Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors Abstract #1578
Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).
Aim(s): The aim of this work is to assess if cumulative dose and dose intensity of everolimus may affect survival of advanced pNETs patients (pts).
Materials and methods: 111 pts (M/F=62/49,median age 54 years) were treated with everolimus for ≥3 months. Cumulative dose (CD) was defined as the total amount of everolimus taken by the pts despite delay or dose reductions; Dose Intensity (DI) was defined as everolimus dose delivered per time unit (mg/day) taken by the pts in a given period of time. According to a ROC analysis, pts were stratified into two groups, with CD<1500 mg (Group A) and CD≥1500 mg (Group B).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Prof. Rossana Berardi
Authors:
Berardi R, Torniai M, Pusceddu S, Spada F, Brizzi M P, Ibrahim T, Antonuzzo L, Ferolla P, Panzuto F, Silvestris N, Partelli S, Bongiovanni A, Zichi C, Riva N, Rinzivillo M
To read results and conclusion, please login ...
Further abstracts you may be interested in
#831 Overall Survival (OS) as a Function of the Number of Therapeutic Lines in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDpNET)
Introduction: At least 9 therapeutic options are now available for unresectable WDpNET patients. Whether all lines can be administrated before tumor or toxic-related deaths is currently unknown.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Amandine Berdelou
Keywords:
pNets
#840 Clinical Impact of Everolimus Cumulative Dose on Pancreatic Neuroendocrine Tumors (pNETs) Outcome
Introduction: Everolimus is approved for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Rossana Berardi
#871 Success with Lutetium-177 DOTATATE Therapy in Cushing’s Syndrome Caused by Functional Pancreatic Neuroendocrine Tumor (pNET) with Ectopic Adrenocorticotropic Hormone (ACTH) Secretion Refractory to Concomitant Everolimus, Pasireotide and Metyrapone
Introduction: We report a case of a 59-year-old female presenting with florid ACTH-dependent Cushing’s syndrome complicated by pulmonary cryptococcal infection.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: Dr Bryan A Chan
#1240 Targeted Therapies as First Line Option in Very Advanced Unresectable Pancreatic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors are an entity of rare, heterogeneous group of tumors that can arise from different sites within the body. Although number of different treatment types and modalities exist, chemotherapy remains as the first line option in the management of advance pancreatic NETS (pNETS); two targeted therapies, sunitinib and everolimus remains available only for second line and beyond in Canada.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: MD Young Soo Rho
#1367 Thymic Neuroendocrine Neoplasia: Therapy with Everolimus
Introduction: Due to the low incidence of 0.02/100 000 no established medical therapy for thymic neuroendocrine neoplasia (t-NEN) exists.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. med. Matthias Lang